{\rtf1\ansi\ansicpg1252\uc1\deff0\deflang2057\deflangfe2057
{\fonttbl
{\f1\fswiss\fprq2\fcharset0 Helvetica;}
{\f2\fmodern\fprq1\fcharset0 Courier;}
}
{\colortbl;
\red0\green0\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red0\green255\blue0;
\red255\green0\blue255;
\red255\green0\blue0;
\red255\green255\blue0;
\red255\green255\blue255;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red0\green51\blue153;
\red204\green204\blue204;
\red100\green149\blue237;
}
{\stylesheet{\widctlpar\adjustright\fs20\cgrid\snext0 Normal;}
{\*\cs10\additive Default Paragraph Font;}}
{\info{\title 9.4 SAS System Output}{\author SAS Version 9.4}{\operator ajay_malkani0}{\version1}}
\widowctrl\ftnbj\aenddoc\formshade\viewkind1\viewscale100\pgbrdrhead\pgbrdrfoot\fet0
\paperw16837\paperh11905\margl720\margr720\margt1440\margb1440
\sectd\linex0\endnhere\pgwsxn16837\pghsxn11905\lndscpsxn
\headery1440\footery1440\marglsxn720\margrsxn720\margtsxn1440\margbsxn1440
{\header\pard\plain\qr\pvmrg\phmrg\posxr\posy0{
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-219\fs19\cf17\qr\f1{Monday, 22 July 2024 20:52:07\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qr\f1\b{{\field{\*\fldinst { PAGE }}}\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
}}
{\*\bkmkstart IDX}{\*\bkmkend IDX}
{\pard\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{1\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{In this review, we have highlighted the scarcity of data outside  North America, Europe and high-income Asia-Pacific countries, leaving the global status of diabetes complications rates unclear, especially in low and middle-income countries. This gap in data stems largely from the lack of population-based systems quantifying healthcare utilisation because surveys and cohort studies are generally inadequate for the assessment of diabetic complications. The comparison of trends in complications has also been hampered by varied reporting methods, definitions of complications and methods to identify people with diabetes. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{CLINICAL OUTCOMES AND FUTURE PERSPECTIVES => XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  1. Declines in all-cause and CVD-related mortality may lead to proportional increases in other forms of  morbidity (e.g. renal disease, infections, cancers, and physical and cognitive disability), with important implications for the clinical and public health burden of diabetes.
2. Future monitoring  of global trends in diabetes complications could been enhanced by implementation of standardised  reporting methods and the establishment of practical registries that suit the dual needs of population monitoring and providing feedback and decision support for clinical systems. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This review of international trends in diabetes-related complications reveals several key conclusions (see Textbox); XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX first,  rates of LEAs, acute complications, CVD and all-cause and CVD-related mortality among populations of people with diabetes are declining.  Data on trends in ESRD, diabetic retinopathy and neuropathy, non-CVD-related causes of death  and \u8216;emerging\u8217; complications in these populations are scarce,  however, and, as such, conclusions are limited. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, inspite of notable declines in several diabetes complications, people with diabetes remain at significantly higher risk for these complications compared with people without diabetes. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, declines in all-cause and CVD-related mortality are leading to proportional increases in other forms of morbidity ,including  renal disease, infections, cancers, and physical and cognitive  disability, with important implications for the clinical and public health burden of diabetes. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Last, there is a genuine lack of  comparable data on trends in rates of diabetes complications, specifically from low-and middle-income countries. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore,  conclusions drawn from this work are limited to about a dozen  high-income countries in North America, Europe and East Asia and ,as such, this l\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{Although the evidence from the present study suggests that these might only be very moderately useful biomarkers in incremental prediction of adverse events in individuals with type 2 diabetes, the pathophysiology underlying these associations and the possibility of intervention studies are intriguing and worthy of further investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The causal pathway may not be unidirectional; a recent Mendelian randomisation study suggests that genetically elevated BCAAs (via impaired catabolism) are associated with increased risk of type 2 diabetes [34], although a better understanding of the underlying pathway is required to increase confidence in this observation [35]. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data strongly support the need for further studies to determine why higher phenylalanine appears to be a consistently adverse signal for CVD outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX That noted, counter-intuitively, we have reported that metformin in fact lowers, not raises, tyrosine levels in individuals with CVD and at high risk of diabetes [16]. The effect of other glucose-lowering drugs on amino acid profiles in individuals with diabetes would now be of interest. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further studies are now needed to validate our novel observations and to examine whether our findings may represent causal pathways. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Most notably, the identification of tyrosine as a potential marker of microvascular risk requires further study.\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\qr\f1{3\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{4\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{We need future studies to define ethnic-specific cut-points for central obesity. Although we did not address obesity as a stand-alone disorder in this statement, there is growing understanding of the neuroendocrine regulation of appetite and energy expenditure that contribute to obesity (435); however, basic science and translational studies are needed to determine whether these mechanisms differ by race / ethnicity.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSex disparities exist in certain endocrine disorders, with autoimmune thyroid disease and cardiovascular complications of diabetes being more common in women than men. The etiology of these sex differences remains unclear and warrants further basic and clinical research. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Data on the prevalence and incidence of osteoporotic fractures in minority men are lacking, suggesting a need for further investigation given the aging of our population. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A major gap in our current understanding of race / ethnic disparities in endocrine disorders is a failure of most studies to specify Hispanic-American and Asian-American subgroups. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this statement, we have attempted to specify ethnic subgroups where they were identified in certain studies; however, the majority of studies did not clearly define subgroups. Where these data are available, there are clear ethnic-specific differences within Hispanic and Asian subgroups, particularly related to diabetes and obesity risk. Thus, it is imperative that future studies accurately identify ethnic subgroups. In general, except for diabetes, there are few data on endocrine disorders in Native Americans and Alaska Natives, an important population for future research as well. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For the endocrine disorders discussed in this statement, there is little evidence that genetic differences are a significant contributor to race / ethnic disparities; however, there is likely significant heterogeneity and admixture among populations, which may mask genetic differences in GWAS studies. As recently reviewed, however, there are emerging techniques t\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
{\pard\par}
\pard\sect\sectd\linex0\endnhere\pgwsxn16837\pghsxn11905\lndscpsxn
\headery1440\footery1440\marglsxn720\margrsxn720\margtsxn1440\margbsxn1440
{\header\pard\plain\qr\pvmrg\phmrg\posxr\posy0{
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-219\fs19\cf17\qr\f1{Monday, 22 July 2024 20:54:42\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qr\f1\b{{\field{\*\fldinst { PAGE }}}\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
}}
{\*\bkmkstart IDX1}{\*\bkmkend IDX1}
{\pard\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{1\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{In this review, we have highlighted the scarcity of data outside  North America, Europe and high-income Asia-Pacific countries, leaving the global status of diabetes complications rates unclear, especially in low and middle-income countries. This gap in data stems largely from the lack of population-based systems quantifying healthcare utilisation because surveys and cohort studies are generally inadequate for the assessment of diabetic complications. The comparison of trends in complications has also been hampered by varied reporting methods, definitions of complications and methods to identify people with diabetes. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{CLINICAL OUTCOMES AND FUTURE PERSPECTIVES => XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  1. Declines in all-cause and CVD-related mortality may lead to proportional increases in other forms of  morbidity (e.g. renal disease, infections, cancers, and physical and cognitive disability), with important implications for the clinical and public health burden of diabetes.
2. Future monitoring  of global trends in diabetes complications could been enhanced by implementation of standardised  reporting methods and the establishment of practical registries that suit the dual needs of population monitoring and providing feedback and decision support for clinical systems. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This review of international trends in diabetes-related complications reveals several key conclusions (see Textbox); XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX first,  rates of LEAs, acute complications, CVD and all-cause and CVD-related mortality among populations of people with diabetes are declining.  Data on trends in ESRD, diabetic retinopathy and neuropathy, non-CVD-related causes of death  and \u8216;emerging\u8217; complications in these populations are scarce,  however, and, as such, conclusions are limited. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, inspite of notable declines in several diabetes complications, people with diabetes remain at significantly higher risk for these complications compared with people without diabetes. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, declines in all-cause and CVD-related mortality are leading to proportional increases in other forms of morbidity ,including  renal disease, infections, cancers, and physical and cognitive  disability, with important implications for the clinical and public health burden of diabetes. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Last, there is a genuine lack of  comparable data on trends in rates of diabetes complications, specifically from low-and middle-income countries. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore,  conclusions drawn from this work are limited to about a dozen  high-income countries in North America, Europe and East Asia and ,as such, this l\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{Although the evidence from the present study suggests that these might only be very moderately useful biomarkers in incremental prediction of adverse events in individuals with type 2 diabetes, the pathophysiology underlying these associations and the possibility of intervention studies are intriguing and worthy of further investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The causal pathway may not be unidirectional; a recent Mendelian randomisation study suggests that genetically elevated BCAAs (via impaired catabolism) are associated with increased risk of type 2 diabetes [34], although a better understanding of the underlying pathway is required to increase confidence in this observation [35]. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data strongly support the need for further studies to determine why higher phenylalanine appears to be a consistently adverse signal for CVD outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX That noted, counter-intuitively, we have reported that metformin in fact lowers, not raises, tyrosine levels in individuals with CVD and at high risk of diabetes [16]. The effect of other glucose-lowering drugs on amino acid profiles in individuals with diabetes would now be of interest. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further studies are now needed to validate our novel observations and to examine whether our findings may represent causal pathways. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Most notably, the identification of tyrosine as a potential marker of microvascular risk requires further study.\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\qr\f1{3\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{4\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{We need future studies to define ethnic-specific cut-points for central obesity. Although we did not address obesity as a stand-alone disorder in this statement, there is growing understanding of the neuroendocrine regulation of appetite and energy expenditure that contribute to obesity (435); however, basic science and translational studies are needed to determine whether these mechanisms differ by race / ethnicity.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSex disparities exist in certain endocrine disorders, with autoimmune thyroid disease and cardiovascular complications of diabetes being more common in women than men. The etiology of these sex differences remains unclear and warrants further basic and clinical research. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Data on the prevalence and incidence of osteoporotic fractures in minority men are lacking, suggesting a need for further investigation given the aging of our population. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A major gap in our current understanding of race / ethnic disparities in endocrine disorders is a failure of most studies to specify Hispanic-American and Asian-American subgroups. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this statement, we have attempted to specify ethnic subgroups where they were identified in certain studies; however, the majority of studies did not clearly define subgroups. Where these data are available, there are clear ethnic-specific differences within Hispanic and Asian subgroups, particularly related to diabetes and obesity risk. Thus, it is imperative that future studies accurately identify ethnic subgroups. In general, except for diabetes, there are few data on endocrine disorders in Native Americans and Alaska Natives, an important population for future research as well. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For the endocrine disorders discussed in this statement, there is little evidence that genetic differences are a significant contributor to race / ethnic disparities; however, there is likely significant heterogeneity and admixture among populations, which may mask genetic differences in GWAS studies. As recently reviewed, however, there are emerging techniques t\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
{\pard\par}
\pard\sect\sectd\linex0\endnhere\pgwsxn16837\pghsxn11905\lndscpsxn
\headery1440\footery1440\marglsxn720\margrsxn720\margtsxn1440\margbsxn1440
{\header\pard\plain\qr\pvmrg\phmrg\posxr\posy0{
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-219\fs19\cf17\qr\f1{Monday, 22 July 2024 20:55:11\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qr\f1\b{{\field{\*\fldinst { PAGE }}}\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
}}
{\*\bkmkstart IDX2}{\*\bkmkend IDX2}
{\pard\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{1\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{In this review, we have highlighted the scarcity of data outside  North America, Europe and high-income Asia-Pacific countries, leaving the global status of diabetes complications rates unclear, especially in low and middle-income countries. This gap in data stems largely from the lack of population-based systems quantifying healthcare utilisation because surveys and cohort studies are generally inadequate for the assessment of diabetic complications. The comparison of trends in complications has also been hampered by varied reporting methods, definitions of complications and methods to identify people with diabetes. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{CLINICAL OUTCOMES AND FUTURE PERSPECTIVES => XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  1. Declines in all-cause and CVD-related mortality may lead to proportional increases in other forms of  morbidity (e.g. renal disease, infections, cancers, and physical and cognitive disability), with important implications for the clinical and public health burden of diabetes.
2. Future monitoring  of global trends in diabetes complications could been enhanced by implementation of standardised  reporting methods and the establishment of practical registries that suit the dual needs of population monitoring and providing feedback and decision support for clinical systems. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This review of international trends in diabetes-related complications reveals several key conclusions (see Textbox); XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX first,  rates of LEAs, acute complications, CVD and all-cause and CVD-related mortality among populations of people with diabetes are declining.  Data on trends in ESRD, diabetic retinopathy and neuropathy, non-CVD-related causes of death  and \u8216;emerging\u8217; complications in these populations are scarce,  however, and, as such, conclusions are limited. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, inspite of notable declines in several diabetes complications, people with diabetes remain at significantly higher risk for these complications compared with people without diabetes. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, declines in all-cause and CVD-related mortality are leading to proportional increases in other forms of morbidity ,including  renal disease, infections, cancers, and physical and cognitive  disability, with important implications for the clinical and public health burden of diabetes. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Last, there is a genuine lack of  comparable data on trends in rates of diabetes complications, specifically from low-and middle-income countries. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore,  conclusions drawn from this work are limited to about a dozen  high-income countries in North America, Europe and East Asia and ,as such, this l\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{Although the evidence from the present study suggests that these might only be very moderately useful biomarkers in incremental prediction of adverse events in individuals with type 2 diabetes, the pathophysiology underlying these associations and the possibility of intervention studies are intriguing and worthy of further investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The causal pathway may not be unidirectional; a recent Mendelian randomisation study suggests that genetically elevated BCAAs (via impaired catabolism) are associated with increased risk of type 2 diabetes [34], although a better understanding of the underlying pathway is required to increase confidence in this observation [35]. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data strongly support the need for further studies to determine why higher phenylalanine appears to be a consistently adverse signal for CVD outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX That noted, counter-intuitively, we have reported that metformin in fact lowers, not raises, tyrosine levels in individuals with CVD and at high risk of diabetes [16]. The effect of other glucose-lowering drugs on amino acid profiles in individuals with diabetes would now be of interest. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further studies are now needed to validate our novel observations and to examine whether our findings may represent causal pathways. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Most notably, the identification of tyrosine as a potential marker of microvascular risk requires further study.\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\qr\f1{3\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{4\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{We need future studies to define ethnic-specific cut-points for central obesity. Although we did not address obesity as a stand-alone disorder in this statement, there is growing understanding of the neuroendocrine regulation of appetite and energy expenditure that contribute to obesity (435); however, basic science and translational studies are needed to determine whether these mechanisms differ by race / ethnicity.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSex disparities exist in certain endocrine disorders, with autoimmune thyroid disease and cardiovascular complications of diabetes being more common in women than men. The etiology of these sex differences remains unclear and warrants further basic and clinical research. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Data on the prevalence and incidence of osteoporotic fractures in minority men are lacking, suggesting a need for further investigation given the aging of our population. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A major gap in our current understanding of race / ethnic disparities in endocrine disorders is a failure of most studies to specify Hispanic-American and Asian-American subgroups. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this statement, we have attempted to specify ethnic subgroups where they were identified in certain studies; however, the majority of studies did not clearly define subgroups. Where these data are available, there are clear ethnic-specific differences within Hispanic and Asian subgroups, particularly related to diabetes and obesity risk. Thus, it is imperative that future studies accurately identify ethnic subgroups. In general, except for diabetes, there are few data on endocrine disorders in Native Americans and Alaska Natives, an important population for future research as well. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For the endocrine disorders discussed in this statement, there is little evidence that genetic differences are a significant contributor to race / ethnic disparities; however, there is likely significant heterogeneity and admixture among populations, which may mask genetic differences in GWAS studies. As recently reviewed, however, there are emerging techniques t\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
{\pard\par}
\pard\sect\sectd\linex0\endnhere\pgwsxn16837\pghsxn11905\lndscpsxn
\headery1440\footery1440\marglsxn720\margrsxn720\margtsxn1440\margbsxn1440
{\header\pard\plain\qr\pvmrg\phmrg\posxr\posy0{
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-219\fs19\cf17\qr\f1{Monday, 22 July 2024 20:56:49\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qr\f1\b{{\field{\*\fldinst { PAGE }}}\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
}}
{\*\bkmkstart IDX3}{\*\bkmkend IDX3}
{\pard\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{1\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{In this review, we have highlighted the scarcity of data outside  North America, Europe and high-income Asia-Pacific countries, leaving the global status of diabetes complications rates unclear, especially in low and middle-income countries. This gap in data stems largely from the lack of population-based systems quantifying healthcare utilisation because surveys and cohort studies are generally inadequate for the assessment of diabetic complications. The comparison of trends in complications has also been hampered by varied reporting methods, definitions of complications and methods to identify people with diabetes. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{CLINICAL OUTCOMES AND FUTURE PERSPECTIVES => XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  1. Declines in all-cause and CVD-related mortality may lead to proportional increases in other forms of  morbidity (e.g. renal disease, infections, cancers, and physical and cognitive disability), with important implications for the clinical and public health burden of diabetes.
2. Future monitoring  of global trends in diabetes complications could been enhanced by implementation of standardised  reporting methods and the establishment of practical registries that suit the dual needs of population monitoring and providing feedback and decision support for clinical systems. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This review of international trends in diabetes-related complications reveals several key conclusions (see Textbox); XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX first,  rates of LEAs, acute complications, CVD and all-cause and CVD-related mortality among populations of people with diabetes are declining.  Data on trends in ESRD, diabetic retinopathy and neuropathy, non-CVD-related causes of death  and \u8216;emerging\u8217; complications in these populations are scarce,  however, and, as such, conclusions are limited. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, inspite of notable declines in several diabetes complications, people with diabetes remain at significantly higher risk for these complications compared with people without diabetes. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, declines in all-cause and CVD-related mortality are leading to proportional increases in other forms of morbidity ,including  renal disease, infections, cancers, and physical and cognitive  disability, with important implications for the clinical and public health burden of diabetes. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Last, there is a genuine lack of  comparable data on trends in rates of diabetes complications, specifically from low-and middle-income countries. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore,  conclusions drawn from this work are limited to about a dozen  high-income countries in North America, Europe and East Asia and ,as such, this l\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{Although the evidence from the present study suggests that these might only be very moderately useful biomarkers in incremental prediction of adverse events in individuals with type 2 diabetes, the pathophysiology underlying these associations and the possibility of intervention studies are intriguing and worthy of further investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The causal pathway may not be unidirectional; a recent Mendelian randomisation study suggests that genetically elevated BCAAs (via impaired catabolism) are associated with increased risk of type 2 diabetes [34], although a better understanding of the underlying pathway is required to increase confidence in this observation [35]. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data strongly support the need for further studies to determine why higher phenylalanine appears to be a consistently adverse signal for CVD outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX That noted, counter-intuitively, we have reported that metformin in fact lowers, not raises, tyrosine levels in individuals with CVD and at high risk of diabetes [16]. The effect of other glucose-lowering drugs on amino acid profiles in individuals with diabetes would now be of interest. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further studies are now needed to validate our novel observations and to examine whether our findings may represent causal pathways. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Most notably, the identification of tyrosine as a potential marker of microvascular risk requires further study.\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\qr\f1{3\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{4\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{We need future studies to define ethnic-specific cut-points for central obesity. Although we did not address obesity as a stand-alone disorder in this statement, there is growing understanding of the neuroendocrine regulation of appetite and energy expenditure that contribute to obesity (435); however, basic science and translational studies are needed to determine whether these mechanisms differ by race / ethnicity.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSex disparities exist in certain endocrine disorders, with autoimmune thyroid disease and cardiovascular complications of diabetes being more common in women than men. The etiology of these sex differences remains unclear and warrants further basic and clinical research. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Data on the prevalence and incidence of osteoporotic fractures in minority men are lacking, suggesting a need for further investigation given the aging of our population. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A major gap in our current understanding of race / ethnic disparities in endocrine disorders is a failure of most studies to specify Hispanic-American and Asian-American subgroups. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this statement, we have attempted to specify ethnic subgroups where they were identified in certain studies; however, the majority of studies did not clearly define subgroups. Where these data are available, there are clear ethnic-specific differences within Hispanic and Asian subgroups, particularly related to diabetes and obesity risk. Thus, it is imperative that future studies accurately identify ethnic subgroups. In general, except for diabetes, there are few data on endocrine disorders in Native Americans and Alaska Natives, an important population for future research as well. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For the endocrine disorders discussed in this statement, there is little evidence that genetic differences are a significant contributor to race / ethnic disparities; however, there is likely significant heterogeneity and admixture among populations, which may mask genetic differences in GWAS studies. As recently reviewed, however, there are emerging techniques t\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
{\pard\par}
\pard\sect\sectd\linex0\endnhere\pgwsxn16837\pghsxn11905\lndscpsxn
\headery1440\footery1440\marglsxn720\margrsxn720\margtsxn1440\margbsxn1440
{\header\pard\plain\qr\pvmrg\phmrg\posxr\posy0{
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-219\fs19\cf17\qr\f1{Monday, 22 July 2024 20:58:07\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qr\f1\b{{\field{\*\fldinst { PAGE }}}\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
}}
{\*\bkmkstart IDX4}{\*\bkmkend IDX4}
{\pard\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{1\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{In this review, we have highlighted the scarcity of data outside  North America, Europe and high-income Asia-Pacific countries, leaving the global status of diabetes complications rates unclear, especially in low and middle-income countries. This gap in data stems largely from the lack of population-based systems quantifying healthcare utilisation because surveys and cohort studies are generally inadequate for the assessment of diabetic complications. The comparison of trends in complications has also been hampered by varied reporting methods, definitions of complications and methods to identify people with diabetes. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{CLINICAL OUTCOMES AND FUTURE PERSPECTIVES => XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  1. Declines in all-cause and CVD-related mortality may lead to proportional increases in other forms of  morbidity (e.g. renal disease, infections, cancers, and physical and cognitive disability), with important implications for the clinical and public health burden of diabetes.
2. Future monitoring  of global trends in diabetes complications could been enhanced by implementation of standardised  reporting methods and the establishment of practical registries that suit the dual needs of population monitoring and providing feedback and decision support for clinical systems. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This review of international trends in diabetes-related complications reveals several key conclusions (see Textbox); XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX first,  rates of LEAs, acute complications, CVD and all-cause and CVD-related mortality among populations of people with diabetes are declining.  Data on trends in ESRD, diabetic retinopathy and neuropathy, non-CVD-related causes of death  and \u8216;emerging\u8217; complications in these populations are scarce,  however, and, as such, conclusions are limited. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, inspite of notable declines in several diabetes complications, people with diabetes remain at significantly higher risk for these complications compared with people without diabetes. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, declines in all-cause and CVD-related mortality are leading to proportional increases in other forms of morbidity ,including  renal disease, infections, cancers, and physical and cognitive  disability, with important implications for the clinical and public health burden of diabetes. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Last, there is a genuine lack of  comparable data on trends in rates of diabetes complications, specifically from low-and middle-income countries. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore,  conclusions drawn from this work are limited to about a dozen  high-income countries in North America, Europe and East Asia and ,as such, this l\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{Although the evidence from the present study suggests that these might only be very moderately useful biomarkers in incremental prediction of adverse events in individuals with type 2 diabetes, the pathophysiology underlying these associations and the possibility of intervention studies are intriguing and worthy of further investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The causal pathway may not be unidirectional; a recent Mendelian randomisation study suggests that genetically elevated BCAAs (via impaired catabolism) are associated with increased risk of type 2 diabetes [34], although a better understanding of the underlying pathway is required to increase confidence in this observation [35]. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data strongly support the need for further studies to determine why higher phenylalanine appears to be a consistently adverse signal for CVD outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX That noted, counter-intuitively, we have reported that metformin in fact lowers, not raises, tyrosine levels in individuals with CVD and at high risk of diabetes [16]. The effect of other glucose-lowering drugs on amino acid profiles in individuals with diabetes would now be of interest. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further studies are now needed to validate our novel observations and to examine whether our findings may represent causal pathways. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Most notably, the identification of tyrosine as a potential marker of microvascular risk requires further study.\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\qr\f1{3\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{4\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{We need future studies to define ethnic-specific cut-points for central obesity. Although we did not address obesity as a stand-alone disorder in this statement, there is growing understanding of the neuroendocrine regulation of appetite and energy expenditure that contribute to obesity (435); however, basic science and translational studies are needed to determine whether these mechanisms differ by race / ethnicity.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSex disparities exist in certain endocrine disorders, with autoimmune thyroid disease and cardiovascular complications of diabetes being more common in women than men. The etiology of these sex differences remains unclear and warrants further basic and clinical research. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Data on the prevalence and incidence of osteoporotic fractures in minority men are lacking, suggesting a need for further investigation given the aging of our population. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A major gap in our current understanding of race / ethnic disparities in endocrine disorders is a failure of most studies to specify Hispanic-American and Asian-American subgroups. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this statement, we have attempted to specify ethnic subgroups where they were identified in certain studies; however, the majority of studies did not clearly define subgroups. Where these data are available, there are clear ethnic-specific differences within Hispanic and Asian subgroups, particularly related to diabetes and obesity risk. Thus, it is imperative that future studies accurately identify ethnic subgroups. In general, except for diabetes, there are few data on endocrine disorders in Native Americans and Alaska Natives, an important population for future research as well. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For the endocrine disorders discussed in this statement, there is little evidence that genetic differences are a significant contributor to race / ethnic disparities; however, there is likely significant heterogeneity and admixture among populations, which may mask genetic differences in GWAS studies. As recently reviewed, however, there are emerging techniques t\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
{\pard\par}
\pard\sect\sectd\linex0\endnhere\pgwsxn16837\pghsxn11905\lndscpsxn
\headery1440\footery1440\marglsxn720\margrsxn720\margtsxn1440\margbsxn1440
{\header\pard\plain\qr\pvmrg\phmrg\posxr\posy0{
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-219\fs19\cf17\qr\f1{Monday, 22 July 2024 20:59:01\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qr\f1\b{{\field{\*\fldinst { PAGE }}}\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
}}
{\*\bkmkstart IDX5}{\*\bkmkend IDX5}
{\pard\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{1\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{In this review, we have highlighted the scarcity of data outside  North America, Europe and high-income Asia-Pacific countries, leaving the global status of diabetes complications rates unclear, especially in low and middle-income countries. This gap in data stems largely from the lack of population-based systems quantifying healthcare utilisation because surveys and cohort studies are generally inadequate for the assessment of diabetic complications. The comparison of trends in complications has also been hampered by varied reporting methods, definitions of complications and methods to identify people with diabetes. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{CLINICAL OUTCOMES AND FUTURE PERSPECTIVES => XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  1. Declines in all-cause and CVD-related mortality may lead to proportional increases in other forms of  morbidity (e.g. renal disease, infections, cancers, and physical and cognitive disability), with important implications for the clinical and public health burden of diabetes.
2. Future monitoring  of global trends in diabetes complications could been enhanced by implementation of standardised  reporting methods and the establishment of practical registries that suit the dual needs of population monitoring and providing feedback and decision support for clinical systems. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This review of international trends in diabetes-related complications reveals several key conclusions (see Textbox); XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX first,  rates of LEAs, acute complications, CVD and all-cause and CVD-related mortality among populations of people with diabetes are declining.  Data on trends in ESRD, diabetic retinopathy and neuropathy, non-CVD-related causes of death  and \u8216;emerging\u8217; complications in these populations are scarce,  however, and, as such, conclusions are limited. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, inspite of notable declines in several diabetes complications, people with diabetes remain at significantly higher risk for these complications compared with people without diabetes. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, declines in all-cause and CVD-related mortality are leading to proportional increases in other forms of morbidity ,including  renal disease, infections, cancers, and physical and cognitive  disability, with important implications for the clinical and public health burden of diabetes. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Last, there is a genuine lack of  comparable data on trends in rates of diabetes complications, specifically from low-and middle-income countries. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore,  conclusions drawn from this work are limited to about a dozen  high-income countries in North America, Europe and East Asia and ,as such, this l\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{Although the evidence from the present study suggests that these might only be very moderately useful biomarkers in incremental prediction of adverse events in individuals with type 2 diabetes, the pathophysiology underlying these associations and the possibility of intervention studies are intriguing and worthy of further investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The causal pathway may not be unidirectional; a recent Mendelian randomisation study suggests that genetically elevated BCAAs (via impaired catabolism) are associated with increased risk of type 2 diabetes [34], although a better understanding of the underlying pathway is required to increase confidence in this observation [35]. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data strongly support the need for further studies to determine why higher phenylalanine appears to be a consistently adverse signal for CVD outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX That noted, counter-intuitively, we have reported that metformin in fact lowers, not raises, tyrosine levels in individuals with CVD and at high risk of diabetes [16]. The effect of other glucose-lowering drugs on amino acid profiles in individuals with diabetes would now be of interest. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further studies are now needed to validate our novel observations and to examine whether our findings may represent causal pathways. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Most notably, the identification of tyrosine as a potential marker of microvascular risk requires further study.\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\qr\f1{3\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{4\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{We need future studies to define ethnic-specific cut-points for central obesity. Although we did not address obesity as a stand-alone disorder in this statement, there is growing understanding of the neuroendocrine regulation of appetite and energy expenditure that contribute to obesity (435); however, basic science and translational studies are needed to determine whether these mechanisms differ by race / ethnicity.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSex disparities exist in certain endocrine disorders, with autoimmune thyroid disease and cardiovascular complications of diabetes being more common in women than men. The etiology of these sex differences remains unclear and warrants further basic and clinical research. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Data on the prevalence and incidence of osteoporotic fractures in minority men are lacking, suggesting a need for further investigation given the aging of our population. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A major gap in our current understanding of race / ethnic disparities in endocrine disorders is a failure of most studies to specify Hispanic-American and Asian-American subgroups. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this statement, we have attempted to specify ethnic subgroups where they were identified in certain studies; however, the majority of studies did not clearly define subgroups. Where these data are available, there are clear ethnic-specific differences within Hispanic and Asian subgroups, particularly related to diabetes and obesity risk. Thus, it is imperative that future studies accurately identify ethnic subgroups. In general, except for diabetes, there are few data on endocrine disorders in Native Americans and Alaska Natives, an important population for future research as well. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For the endocrine disorders discussed in this statement, there is little evidence that genetic differences are a significant contributor to race / ethnic disparities; however, there is likely significant heterogeneity and admixture among populations, which may mask genetic differences in GWAS studies. As recently reviewed, however, there are emerging techniques t\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
{\pard\par}
\pard\sect\sectd\linex0\endnhere\pgwsxn16837\pghsxn11905\lndscpsxn
\headery1440\footery1440\marglsxn720\margrsxn720\margtsxn1440\margbsxn1440
{\header\pard\plain\qr\pvmrg\phmrg\posxr\posy0{
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-219\fs19\cf17\qr\f1{Monday, 22 July 2024 21:01:33\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qr\f1\b{{\field{\*\fldinst { PAGE }}}\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
}}
{\*\bkmkstart IDX6}{\*\bkmkend IDX6}
{\pard\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{1\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{In this review, we have highlighted the scarcity of data outside  North America, Europe and high-income Asia-Pacific countries, leaving the global status of diabetes complications rates unclear, especially in low and middle-income countries. This gap in data stems largely from the lack of population-based systems quantifying healthcare utilisation because surveys and cohort studies are generally inadequate for the assessment of diabetic complications. The comparison of trends in complications has also been hampered by varied reporting methods, definitions of complications and methods to identify people with diabetes. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{CLINICAL OUTCOMES AND FUTURE PERSPECTIVES => XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  1. Declines in all-cause and CVD-related mortality may lead to proportional increases in other forms of  morbidity (e.g. renal disease, infections, cancers, and physical and cognitive disability), with important implications for the clinical and public health burden of diabetes.
2. Future monitoring  of global trends in diabetes complications could been enhanced by implementation of standardised  reporting methods and the establishment of practical registries that suit the dual needs of population monitoring and providing feedback and decision support for clinical systems. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This review of international trends in diabetes-related complications reveals several key conclusions (see Textbox); XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX first,  rates of LEAs, acute complications, CVD and all-cause and CVD-related mortality among populations of people with diabetes are declining.  Data on trends in ESRD, diabetic retinopathy and neuropathy, non-CVD-related causes of death  and \u8216;emerging\u8217; complications in these populations are scarce,  however, and, as such, conclusions are limited. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, inspite of notable declines in several diabetes complications, people with diabetes remain at significantly higher risk for these complications compared with people without diabetes. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, declines in all-cause and CVD-related mortality are leading to proportional increases in other forms of morbidity ,including  renal disease, infections, cancers, and physical and cognitive  disability, with important implications for the clinical and public health burden of diabetes. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Last, there is a genuine lack of  comparable data on trends in rates of diabetes complications, specifically from low-and middle-income countries. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore,  conclusions drawn from this work are limited to about a dozen  high-income countries in North America, Europe and East Asia and ,as such, this l\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{Although the evidence from the present study suggests that these might only be very moderately useful biomarkers in incremental prediction of adverse events in individuals with type 2 diabetes, the pathophysiology underlying these associations and the possibility of intervention studies are intriguing and worthy of further investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The causal pathway may not be unidirectional; a recent Mendelian randomisation study suggests that genetically elevated BCAAs (via impaired catabolism) are associated with increased risk of type 2 diabetes [34], although a better understanding of the underlying pathway is required to increase confidence in this observation [35]. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data strongly support the need for further studies to determine why higher phenylalanine appears to be a consistently adverse signal for CVD outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX That noted, counter-intuitively, we have reported that metformin in fact lowers, not raises, tyrosine levels in individuals with CVD and at high risk of diabetes [16]. The effect of other glucose-lowering drugs on amino acid profiles in individuals with diabetes would now be of interest. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further studies are now needed to validate our novel observations and to examine whether our findings may represent causal pathways. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Most notably, the identification of tyrosine as a potential marker of microvascular risk requires further study.\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\qr\f1{3\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{4\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{We need future studies to define ethnic-specific cut-points for central obesity. Although we did not address obesity as a stand-alone disorder in this statement, there is growing understanding of the neuroendocrine regulation of appetite and energy expenditure that contribute to obesity (435); however, basic science and translational studies are needed to determine whether these mechanisms differ by race / ethnicity.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSex disparities exist in certain endocrine disorders, with autoimmune thyroid disease and cardiovascular complications of diabetes being more common in women than men. The etiology of these sex differences remains unclear and warrants further basic and clinical research. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Data on the prevalence and incidence of osteoporotic fractures in minority men are lacking, suggesting a need for further investigation given the aging of our population. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A major gap in our current understanding of race / ethnic disparities in endocrine disorders is a failure of most studies to specify Hispanic-American and Asian-American subgroups. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this statement, we have attempted to specify ethnic subgroups where they were identified in certain studies; however, the majority of studies did not clearly define subgroups. Where these data are available, there are clear ethnic-specific differences within Hispanic and Asian subgroups, particularly related to diabetes and obesity risk. Thus, it is imperative that future studies accurately identify ethnic subgroups. In general, except for diabetes, there are few data on endocrine disorders in Native Americans and Alaska Natives, an important population for future research as well. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For the endocrine disorders discussed in this statement, there is little evidence that genetic differences are a significant contributor to race / ethnic disparities; however, there is likely significant heterogeneity and admixture among populations, which may mask genetic differences in GWAS studies. As recently reviewed, however, there are emerging techniques t\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
{\pard\par}
\pard\sect\sectd\linex0\endnhere\pgwsxn16837\pghsxn11905\lndscpsxn
\headery1440\footery1440\marglsxn720\margrsxn720\margtsxn1440\margbsxn1440
{\header\pard\plain\qr\pvmrg\phmrg\posxr\posy0{
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-219\fs19\cf17\qr\f1{Monday, 22 July 2024 21:02:37\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
\trowd\trkeep\trqr\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qr\f1\b{{\field{\*\fldinst { PAGE }}}\cell}
\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
}}
{\*\bkmkstart IDX7}{\*\bkmkend IDX7}
{\pard\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{1\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{In this review, we have highlighted the scarcity of data outside  North America, Europe and high-income Asia-Pacific countries, leaving the global status of diabetes complications rates unclear, especially in low and middle-income countries. This gap in data stems largely from the lack of population-based systems quantifying healthcare utilisation because surveys and cohort studies are generally inadequate for the assessment of diabetic complications. The comparison of trends in complications has also been hampered by varied reporting methods, definitions of complications and methods to identify people with diabetes. XXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{CLINICAL OUTCOMES AND FUTURE PERSPECTIVES => XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX  1. Declines in all-cause and CVD-related mortality may lead to proportional increases in other forms of  morbidity (e.g. renal disease, infections, cancers, and physical and cognitive disability), with important implications for the clinical and public health burden of diabetes.
2. Future monitoring  of global trends in diabetes complications could been enhanced by implementation of standardised  reporting methods and the establishment of practical registries that suit the dual needs of population monitoring and providing feedback and decision support for clinical systems. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX This review of international trends in diabetes-related complications reveals several key conclusions (see Textbox); XXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX first,  rates of LEAs, acute complications, CVD and all-cause and CVD-related mortality among populations of people with diabetes are declining.  Data on trends in ESRD, diabetic retinopathy and neuropathy, non-CVD-related causes of death  and \u8216;emerging\u8217; complications in these populations are scarce,  however, and, as such, conclusions are limited. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Second, inspite of notable declines in several diabetes complications, people with diabetes remain at significantly higher risk for these complications compared with people without diabetes. XXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Third, declines in all-cause and CVD-related mortality are leading to proportional increases in other forms of morbidity ,including  renal disease, infections, cancers, and physical and cognitive  disability, with important implications for the clinical and public health burden of diabetes. XXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Last, there is a genuine lack of  comparable data on trends in rates of diabetes complications, specifically from low-and middle-income countries. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Therefore,  conclusions drawn from this work are limited to about a dozen  high-income countries in North America, Europe and East Asia and ,as such, this l\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{Although the evidence from the present study suggests that these might only be very moderately useful biomarkers in incremental prediction of adverse events in individuals with type 2 diabetes, the pathophysiology underlying these associations and the possibility of intervention studies are intriguing and worthy of further investigation. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX The causal pathway may not be unidirectional; a recent Mendelian randomisation study suggests that genetically elevated BCAAs (via impaired catabolism) are associated with increased risk of type 2 diabetes [34], although a better understanding of the underlying pathway is required to increase confidence in this observation [35]. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Our data strongly support the need for further studies to determine why higher phenylalanine appears to be a consistently adverse signal for CVD outcomes. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX That noted, counter-intuitively, we have reported that metformin in fact lowers, not raises, tyrosine levels in individuals with CVD and at high risk of diabetes [16]. The effect of other glucose-lowering drugs on amino acid profiles in individuals with diabetes would now be of interest. XXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Further studies are now needed to validate our novel observations and to examine whether our findings may represent causal pathways. XXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Most notably, the identification of tyrosine as a potential marker of microvascular risk requires further study.\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\qr\f1{3\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\ql\f1\b{Continued\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx15397
{\row}
{\pard\page\par}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb10\sa10\sl-297\fs25\cf17\qc\f1\b{Diabetes macrovascular complications data set 3\cell}
\cltxlrtb\clvertalt\clcbpat8\clpadt10\clpadft3\clpadr10\clpadfr3\cellx15397
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}


\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\qr\f1\b{sub_ref_no\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Strengths\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Weaknesses\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\qr\f1{4\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx1985
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx8287
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf18\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx14589
{\row}
\trowd\trkeep\trqc\trgaph0
\pard\plain\intbl\sb0\sa0\sl-226\fs19\cf17\qc\f1\b{\cell}
\clbrdrt\brdrs\brdrw10\brdrcf0\clbrdrb\brdrs\brdrw10\brdrcf0\clbrdrr\brdrs\brdrw10\brdrcf0\clbrdrl\brdrs\brdrw10\brdrcf0\cltxlrtb\clvertalt\clcbpat8\cellx10
{\row}

\trowd\trkeep\trhdr\trleft797\trgaph0
\pard\plain\intbl\keepn\sb67\sa67\sl-226\fs19\cf8\ql\f1\b{Future_Research\cell}
\clbrdrt\brdrs\brdrw10\brdrcf1\clbrdrb\brdrs\brdrw10\brdrcf18\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalb\clcbpat19\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
\trowd\trkeep\trleft797\trgaph0
\pard\plain\intbl\sb67\sa67\sl-219\fs19\cf1\ql\f1{We need future studies to define ethnic-specific cut-points for central obesity. Although we did not address obesity as a stand-alone disorder in this statement, there is growing understanding of the neuroendocrine regulation of appetite and energy expenditure that contribute to obesity (435); however, basic science and translational studies are needed to determine whether these mechanisms differ by race / ethnicity.  XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXSex disparities exist in certain endocrine disorders, with autoimmune thyroid disease and cardiovascular complications of diabetes being more common in women than men. The etiology of these sex differences remains unclear and warrants further basic and clinical research. XXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Data on the prevalence and incidence of osteoporotic fractures in minority men are lacking, suggesting a need for further investigation given the aging of our population. XXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX A major gap in our current understanding of race / ethnic disparities in endocrine disorders is a failure of most studies to specify Hispanic-American and Asian-American subgroups. XXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX In this statement, we have attempted to specify ethnic subgroups where they were identified in certain studies; however, the majority of studies did not clearly define subgroups. Where these data are available, there are clear ethnic-specific differences within Hispanic and Asian subgroups, particularly related to diabetes and obesity risk. Thus, it is imperative that future studies accurately identify ethnic subgroups. In general, except for diabetes, there are few data on endocrine disorders in Native Americans and Alaska Natives, an important population for future research as well. XXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX For the endocrine disorders discussed in this statement, there is little evidence that genetic differences are a significant contributor to race / ethnic disparities; however, there is likely significant heterogeneity and admixture among populations, which may mask genetic differences in GWAS studies. As recently reviewed, however, there are emerging techniques t\cell}
\clbrdrb\brdrs\brdrw10\brdrcf1\clbrdrr\brdrs\brdrw10\brdrcf1\clbrdrl\brdrs\brdrw10\brdrcf1\cltxlrtb\clvertalt\clcbpat8\clpadt67\clpadft3\clpadr67\clpadfr3\cellx7099
{\row}
}
